Increased radioiodine uptake of thyroid cell cultures after external irradiation

Strahlentherapie und Onkologie

Volumn 182, Issue 1, 2006, Pages 30-36

  Meller, Birgit ^a   Deisting, Wibke ^a   Wenzel, Björn E ^a   Pethe, Annette ^b   Nadrowitz, Roger ^a   Meller, Johannes ^c   Richter, Eckart ^a   Baehre, Manfred ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

131I uptake; FRTL 5; Iodine; Irradiation; ML 1; Thyroid

Indexed keywords

IODINE 131; SODIUM PERCHLORATE;

ARTICLE; CANCER RADIOTHERAPY; CELL COUNT; CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG UPTAKE; HUMAN; HUMAN CELL; INCUBATION TIME; PHOTON; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THYROID CELL;

ANIMALS; CELL COUNT; CELL LINE; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IODIDES; IODINE RADIOISOTOPES; PERCHLORIC ACID; PHOTONS; RADIATION DOSAGE; RATS; SODIUM COMPOUNDS; THYROID GLAND; TIME FACTORS;

EID: 30344489005     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-006-1442-y     Document Type: Article

References (51)

1. Ambesi-Impiombato FS, Parks LAM, Coon HG. Culture of hormone-dependent functional epithelial cells from rat thyroids. Proc Natl Acad Sci USA 1980;77:3455-9.
2. Bauer R. Physikalische Grundlagen der Radioiodtherapie. In: Buttermann G, Hrsg. Radiojodtherapie bei Schilddrüsenerkrankungen. Indikationen - Ergebnisse - Nebenwirkungen. Frankfurt: pmi, 1887:3-21.
3. Bernhardt P, Ahlman H, Forssell-Aronsson E. Modelling of metastatic cure after radionuclide therapy: influence of tumor distribution, cross-irradiation, and variable activity concentration. Med Phys 2004;31:2628-35.
4. Brunner TB, Hahn SM, McKenna WG, et al. Radiation sensitization by inhibition of activated Ras. Strahlenther Onkol 2004;180:731-40.
5. Caillou B, Troalen F, Baudin E, et al. Na1/I2 symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab 1998;83:4102-6.
6. 131I. J Nucl Med 2000;41:1198-202.
7. Coelho SM, Corbo R, Buescu A, et al. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J Endocrinol Invest 2004;27:334-9.
8. De La Vieja A, Dohan O, Levy O, et al. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000;80:1083-105.
9. Emfietzoglou D, Kostarelos K, Papakostas A, et al. Liposome-mediated radiotherapeutics within avascular tumor spheroids: comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody. J Nucl Med 2005;46:89-97.
10. Eskandari S, Loo DD, Dai G, et al. Thyroid Na+/I- symporter. Mechanism, stoichiometry, and specificity. J Biol Chem 1997;272:27230-8.
11. Fujibayashi Y, Waki A, Sakahara H, et al. Transient increase in glycolytic metabolism in cultured tumor cells immediately after exposure to ionising radiation: from gene expression to deoxyglucose uptake. Radiat Res 1997;147:729-34.
12. Furuta M, Hasegawa M, Hayakawa K, et al. Rapid rise in FDG uptake in an irradiated human tumour xenograft. Eur J Nucl Med 1997;24:435-8.
13. Gerlach B, Harder AH, Hulsebos TJM, et al. Radiosensitivity and TP53, EGFR amplification and LOH10 analysis of primary glioma cell cultures. Strahlenther Onkol 2002;178:491-6.
14. Grollman EF, Smolar A, Ommaya A, et al. Iodine suppression of iodide uptake in FRTL-5 thyroid cells. Endocrinology 1986;118:2477-82.
15. Haugen BR. Redifferentiation therapy in advanced thyroid cancer. Curr Drug Targets Immune Endocr Metab Disord 2004;4:175-80.
16. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D- glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993;34:773-9.
17. Higashi T, Fisher SJ, Brown RS, et al. Evaluation of the early effect of local irradiation on normal rodent bone marrow metabolism using FDG: preclinical PET studies. J Nucl Med 2000;41:2026-35.
18. Jarzab B, Handkiewicz-Junak D, Roskosz J, et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. Eur J Nucl Med Mol Imaging 2003;30:1077-86.
19. Jhiang SM, Cho J, Ryu KY, et al. An immunohistochemical study of Na1/I2 symporter in human thyroid tissues and salivary gland tissues. Endocrinology 1998;139:4416-9.
20. Kao CH, Yen TC. Stunning effects after a diagnostic dose of iodine-131. Nuklearmedizin 1998;37:23-5.
21. Kutta H, Kampen U, Sagowski W, et al. Amifostine is a potent radioprotector of salivary glands in radioiodine therapy. Structural and ultrastructural findings. Strahlenther Onkol 2005;181:237-45.
22. 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004;45:619-25.
23. Maruyama I, Sadato N, Waki A, et al. Hyperacute changes in glucose metabolism of brain tumors after stereotactic radiosurgery: a PET study. J Nucl Med 1999;40:1085-90.
24. Mayer R, Hamilton-Farrell MR, van der Kleij AJ, et al. Hyperbaric oxygen and radiotherapy. Strahlenther Onkol 2005;181:113-23.
25. 131I-induced release of "cold" iodine stored in the thyroid. Nuklearmedizin 2005;44:137-42.
26. 131I diagnostic activities and radioiodine therapy on urinary iodine excretion in patients with differentiated thyroid carcinoma. Nuklearmedizin 2005;44:243-7.
27. Meller B, Lauer I, Bähre M, et al. Influence of radioiodine therapy on urinary iodine excretion. Nuklearmedizin 1998;37:107-12.
28. Muratet JP, Daver A, Minier JF, et al. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998;39:1546-50.
29. Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 2004;15:319-28.
30. Nusser NN, Bartkowiak D, Röttinger EM. The influence of bromodeoxyuridine on the induction and repair of DNA double-strand breaks in glioblastoma cells. Strahlenther Onkol 2002;178:504-9.
31. Österreicher J, Prise KM, Michael BD, et al. Radiation-induced bystander effects. Mechanisms, biological implications, and current investigations at the Leipzig LIPSION facility. Strahlenther Onkol 2003;179:69-77.
32. Ohira H, Kubota K, Ohuchi N, et al. Comparison of intratumoral distribution of 99mTc-MIBI and deoxyglucose in mouse breast cancer models. J Nucl Med 2000;41:1561-8.
33. 131I irradiation in cultured thyroid epithelial cells. J Nucl Med 2002;43:828-34.
34. Riemann B, Könemann S, Pöpping D, et al. Early effects of irradiation on [(123)I]-IMT and [(18)F]-FDG uptake in rat C6 glioma cells. Strahlenther Onkol 2004;180:434-41.
35. Saito T, Endo T, Kawaguchi A, et al. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 1998;101:1296-300.
36. Schlemmer HP, Becker M, Bachert P, et al. Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Cancer Res 1999;59:2363-9.
37. Saur HB, Lerch H, Schober O. The survival rate of patients with a differentiated thyroid carcinoma without primary percutaneous irradiation of the neck area. Strahlenther Onkol 1996;172:306-11.
38. Schmutzler C. Regulation of the sodium/iodide symporter by retinoids - a review. Exp Clin Endocrinol Diabetes 2001;109:41-4.
39. Schmutzler C, Köhrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000;10:393-406.
40. Schönberger J, Bauer J, Spruss T, et al. Establishment and characterization of the follicular thyroid carcinoma cell line ML-1. J Mol Med 2000;78:102-10.
41. Schuck A, Biermann M, Pixberg MK, et al. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS). Strahlenther Onkol 2003;179:832-9.
42. Senekowitsch-Schmidtke R, Matzen K, Truckenbrodt R, et al. Tumor cell spheroids as a model for evaluation of metabolic changes after irradiation. J Nucl Med 1998;39:1762-8.
43. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.
44. Stiblar-Martincic D, Cor A. The effect of irradiation on FRTL-5 cell morphology. Folia Biol (Praha) 1998;44:173-6.
45. Sviderskaya EV, Jazrawi E, Baldwin SA, et al. Cellular stress causes accumulation of the glucose transporter at the surface of cells independently of their insulin sensitivity. J Membr Biol 1996;149:133-40.
46. Tsang RW, Brierley JD, Simpson WJ, et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998;82:375-88.
47. 131I and 67Ga. Int J Radiat Oncol Biol Phys 1994;30:447-54.
48. Weiss SJ, Philip NJ, Ambesi-Impiombato FS, et al. Thyrotropin-stimulated iodide transport mediated by cyclic AMP and dependent on protein synthesis. Endocrinology 1984;114:1099-107.
49. Weiss SJ, Philip NJ, Grollman EF. Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology 1984;114:1090-8.
50. Widnell CC, Baldwin SA, Davies A, et al. Cellular stress induces a redistribution of the glucose transporter. FASEB J 1990;4:1634-7.
51. Yamamoto T, Nishizawa S, Maruyama I, et al. Acute effects of stereotactic radiosurgery on the kinetics of glucose metabolism in metastatic brain tumors: FDG PET study. Ann Nucl Med 2001;15:103-9.